Annals of Oncology Advance Access originally published online on June 9, 2005
Annals of Oncology 2005 16(7):1133-1139; doi:10.1093/annonc/mdi207
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy
1 Divisione di Oncologia Medica, 2 1a Divisione Clinicizzata di Chirurgia Generale, 3 Divisione di Radioterapia Oncologica, 4 Servizio di Anatomia Patologica, Azienda Ospedaliera-Università di Verona, Verona; 5 Divisione di Anatomia Patologica e Medicina di Laboratorio, Istituto Europeo di Oncologia, Milan, Italy
* Correspondence to: Dr F. Pasini, Divisione di Oncologia Medica, Ospedale Civile Maggiore, Piazzale Stefani 1, 37 126 Verona, Italy. Tel: +39-(0)45-8072342; Fax: +39-(0)45-8341277; Email: felice.pasini{at}univr.it
Background: This phase I study was aimed at defining the toxicity profile and pathological response rate of a neoadjuvant schedule including weekly docetaxel and cisplatin, protracted venous infusion (PVI) of 5-FU and concomitant radiotherapy (RT) in locally advanced esophageal cancer.
Patients and methods: The schedule consisted of a first phase of chemotherapy alone and a second phase of concurrent chemoradiation. Initial doses were: docetaxel and cisplatin 20 mg/m2 on days 1, 8, 15, 29, 36 and 43 plus 5-FU 150 mg/m2 PVI on days 1–21 and 29–49; RT (40 Gy) started on day 29. In the following steps the doses were escalated up to docetaxel 35 mg/m2 and cisplatin 25 mg/m2 on days 1, 8, 15, 29, 36, 43, 50 and 57 plus 5-FU 180 mg/m2 PVI on days 1–21 and 150 mg/m2 PVI on days 29–63 concurrently with RT 50 Gy.
Results: Forty-seven patients were enrolled and 46 completed the planned treatment. During the concomitant phase, grade 3–4 hematological toxicities occurred in three patients (6.5%) (or 3/174 cycles) and non-hematological toxicities in six patients (13%) (or 7/179 cycles). A pathological downstaging was obtained in 59.6% of the cases (28/47): complete remission (pCR) in 14 patients, near pCR (residual microfoci on the primary pN0) in eight patients, pT2 pN0 in three patients and partial response on the primary with positive lymph nodes in three patients. Six (13%) and 13 (28%) patients were considered stable and non-responders, respectively. In the last dose level, eight pCR and four near-pCR were obtained out of 15 patients. The maximum tolerable dose was not formally defined because dose escalation was stopped at the last dose level.
Conclusion: This schedule represents a feasible treatment and the high pathological response rate is extremely encouraging; the doses found in the last dose-level are the basis for an ongoing phase II study at our institution.
Key words: esophageal cancer, chemoradiotherapy, docetaxel, weekly chemotherapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Pedrazzani, G. de Manzoni, D. Marrelli, S. Giacopuzzi, G. Corso, A. M. Minicozzi, B. Rampone, and F. Roviello Lymph node involvement in advanced gastroesophageal junction adenocarcinoma J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 378 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C-C Lin, C-H Hsu, J. Cheng, H-P Wang, J-M Lee, K-H Yeh, C-H Yang, J-T Lin, A-L Cheng, and Y-C Lee Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer Ann. Onc., January 1, 2007; 18(1): 93 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Apisarnthanarax, M. M. Alauddin, F. Mourtada, H. Ariga, U. Raju, O. Mawlawi, D. Han, W. G. Bornmann, J. A. Ajani, L. Milas, et al. Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3'-Deoxy-3'-3H-Fluorothymidine Using Preclinical Tumor Models Clin. Cancer Res., August 1, 2006; 12(15): 4590 - 4597. [Abstract] [Full Text] [PDF]
|
|